Welcome to our dedicated page for NuVasive news (Ticker: NUVA), a resource for investors and traders seeking the latest updates and insights on NuVasive stock.
NuVasive, Inc. (NASDAQ: NUVA) is a leader in spine technology innovation, dedicated to transforming spine surgery with minimally disruptive, procedurally integrated solutions. Headquartered in San Diego, NuVasive aims to advance surgical care and improve patient outcomes through its extensive product portfolio and global reach.
The company’s core offerings include surgical access instruments, spinal implants, fixation systems, biologics, and software for surgical planning. NuVasive also provides navigation and imaging solutions, magnetically adjustable implant systems for both spine and orthopedics, and intraoperative neuromonitoring technology and services. With an emphasis on speed of innovation, NuVasive continually develops new products to meet the evolving needs of spine surgeons, hospitals, and patients.
NuVasive has shown robust financial performance, with over $1 billion in net sales and operations in more than 50 countries. The company's recent achievements include a 2.4% increase in total net sales for the second quarter of 2023, reaching $317.8 million. This growth is driven by the adoption of new products and higher procedural volumes in the U.S.
The company is on the path to combining with Globus Medical, which is anticipated to drive further value creation for shareholders and expand its impact on improving patient lives globally. This merger is expected to enhance NuVasive's ability to deliver innovative and clinically proven outcomes.
NuVasive also emphasizes corporate social responsibility through initiatives like the NuVasive Spine Foundation®, which provides life-changing spinal surgery to disadvantaged communities, and other patient-to-patient support programs.
For more information, visit www.nuvasive.com.
NuVasive, a leader in spine technology, announced participation as a silver sponsor at the CSRS 48th Annual Meeting from December 9-12, 2020. The company will showcase its innovative C360 cervical spine portfolio, including the newly launched anterior cervical plating system. Key features include the thinnest plate on the market, varied implant lengths for diverse anatomies, and advanced screw options. NuVasive's portfolio aims to enhance surgical outcomes and reflects their commitment to advancing cervical spine care.
NuVasive, Inc. (NASDAQ: NUVA) has launched its new C360™ cervical spine portfolio, highlighting the commercial introduction of the Anterior Cervical Plating (ACP) system, which features the industry's thinnest plate at 1.6 mm. This innovation aims to reduce common postoperative complications and supports customized treatment for patients. The cervical spine market is valued at approximately $2.6 billion, representing significant growth potential for NuVasive. Additionally, the C360 portfolio will include a new posterior fixation system, Reline® Cervical, available in 2021.
NuVasive, Inc. (NASDAQ: NUVA) announced its participation in one-on-one investor meetings at the Piper Sandler 32nd Annual Virtual Healthcare Conference on December 2-3, 2020. A pre-recorded fireside chat will be available for registered attendees during the week of November 23, 2020, and can be accessed via the Company’s website. NuVasive specializes in spine technology, offering minimally invasive surgical solutions. The Company reported over $1 billion in net sales and operates in more than 50 countries.
NuVasive, Inc. (NASDAQ: NUVA) has announced the launch of the Cohere® XLIF®, the first Porous PEEK™ interbody for eXtreme Lateral Interbody Fusion (XLIF) surgeries. This innovative product is designed to enhance bone in-growth and improve stability, outperforming traditional smooth PEEK implants. In tandem, the company introduced the Cohere XLIF AMS plate, which provides additional fixation options in surgical procedures. Early studies indicate that patients using Porous PEEK experience better outcomes in pain and disability scores compared to standard implants.
NuVasive, Inc. (NASDAQ: NUVA) received FDA 510(k) clearance for its thoracolumbar interbody portfolio to treat multi-level sagittal deformities of the thoracolumbar spine. This expands treatment options from one- and two-level surgeries to multiple levels, offering significant improvements in spine alignment. The portfolio includes implants like Cohere® and Modulus® and integrates with the Integrated Global Alignment® (iGA®) platform. This clearance enhances NuVasive's position as a leader in spinal technology and aims to improve patient outcomes through innovative surgical solutions.
NuVasive, Inc. (NASDAQ: NUVA) will present at the Credit Suisse 29th Annual Virtual Healthcare Conference on November 9, 2020, at 11:00 a.m. ET. The presentation will focus on the company's innovation in spine technology aimed at transforming surgery with minimally invasive solutions.
A live webcast will be available on their website, with a replay accessible for 30 days post-event. NuVasive is a leader in spine solutions, delivering over $1 billion in net sales and operating in over 50 countries.
NuVasive, Inc. (NASDAQ: NUVA) reported a 1.5% increase in net sales to $295.3 million for Q3 2020, with a GAAP operating margin of 9.2% and non-GAAP operating margin of 15.8%. GAAP diluted EPS was $0.11, while non-GAAP diluted EPS stood at $0.55. The company noted a faster recovery from COVID-19 impacts, highlighted by growth in the international market. However, NuVasive opted not to reinstate annual financial guidance amid ongoing uncertainties.
NuVasive, Inc. (NASDAQ: NUVA) announced its participation as a gold level sponsor at the Society for Minimally Invasive Spine Surgery (SMISS) Annual Forum, taking place virtually from October 29-31, 2020. The company, committed as a platinum sponsor for the next three years, aims to enhance education on less invasive spine surgeries. During the event, NuVasive will host two workshops focusing on advanced materials science and single-position surgery techniques. Additionally, the company will exhibit its technological innovations designed to improve surgical outcomes.
NuVasive, Inc. (NASDAQ: NUVA), a leader in spine technology, will release its third quarter 2020 earnings results on October 29, 2020, after market close. A conference call to discuss financial performance will occur the same day at 4:30 p.m. ET. Domestic and international callers can dial 1-877-407-9039 and 1-201-689-8470, respectively. A live webcast will be available on the company's Investor Relations page, and replays will be accessible until November 5, 2020, for telephone and until November 29, 2020 for the webcast.
NuVasive, Inc. (NASDAQ: NUVA) has announced a new leadership structure to enhance global commercial operations and product organization. This restructuring introduces a global commercial leader and consolidates product and services teams under one executive to drive growth, aiming to double international net sales by 2024. Massimo Calafiore has been promoted to executive vice president of Global Business Units, while Brent Boucher joins as executive vice president of Global Commercial. The changes aim to improve execution and align with the company’s long-term strategy.
FAQ
What is the market cap of NuVasive (NUVA)?
What does NuVasive, Inc. specialize in?
Where is NuVasive headquartered?
What are some of NuVasive's core products?
How did NuVasive perform in the second quarter of 2023?
Is NuVasive involved in any mergers or acquisitions?
How does NuVasive contribute to social responsibility?
What is the mission of NuVasive, Inc.?
In how many countries does NuVasive operate?
What recent financial milestone has NuVasive achieved?
Where can I find more information about NuVasive?
